Objective: Leptin, a hormone secreted by adipocytes, plays a crucial role in regulating energy balance. Estrogen, like leptin, reduces food intake and adiposity while increasing energy expenditure in animals and humans of both sexes through its actions on the central nervous system. We reviewed the literature for studies of the effects of exogenously administered estrogen on serum leptin concentrations and adiposity in women.
I n humans, signaling molecules and feedback systems regulate food consumption and satiety states to ensure that energy intake matches energy expenditure across time, a process called energy homeostasis. 1 The brain regulates energy homeostasis in response to signals from both adipose tissue and the gastrointestinal tract. 2 Leptin, a peptide hormone, plays a key role in this regulatory process. Leptin is synthesized and secreted by white adipocytes, the major form of stored energy in the body. 3 Leptin circulates at levels proportional to body fat content 4 then enters the central nervous system across the blood-brain barrier in proportion to circulating plasma levels. 5 Administration of exogenous leptin reduces both spontaneous and fasting-induced hyperphagia, whereas chronic peripheral administration reduces food intake and fat mass. 6<8 Disruption in leptin signaling, such as in animals or humans deficient in leptin 3, 9 or its receptors, 10, 11 causes an obese, hyperphagic phenotype.
Like leptin, treatment with estrogen also reduces food intake and adiposity while increasing energy expenditure in female animals and humans. Ovariectomy in female rats results in a sharp decrease in estrogen and an increase in body weight, but this weight gain is reversible by estrogen therapy (ET). Such results suggest that the cause of ovariectomy-induced obesity may be lack of estrogen. 12, 13 Furthermore, the effects of estrogen on adiposity are apparently mediated by its actions on estrogen receptor-> (ER->) because mice with ER-> global deletion are obese. 14 The brain is implicated in these effects because site-specific destruction of ER-> in the ventromedial hypothalamus also induces obesity. 15 In addition, ER-> is colocalized with leptin receptor expression in regions of the hypothalamus, 16 and this colocalization suggests a potential scenario in which the two signaling pathways interact to regulate energy balance.
Both peripheral and central administrations of estradiol to ovariectomized female rats restore central leptin sensitivity and return body fat distribution to that of a female rat with intact ovaries. 17 These findings provide the rationale for an analogous investigation examining the relationship between estrogen and leptin in humans. Human menopause is associated with a decrease in serum estrogen levels and changes in energy expenditure and body composition. 18 In particular, the increased deposition of intra-abdominal fat in postmenopausal women has been tentatively linked to estrogen depletion, perhaps causally in early menopause. 19, 20 Postmenopausal women who receive estradiol do not display the characteristic pattern of abdominal weight gain usually associated with menopause, suggesting that estrogen insufficiency may contribute to the increase in adiposity during menopause.
In response to these findings from animal and human studies, we sought to identify experimental evidence from randomized, placebo-controlled trials in humans regarding a direct effect of exogenous estrogen on serum leptin concentrations. We reviewed the literature to evaluate whether estrogen administration in the form of hormone therapy (HT) in postmenopausal women had any effect on serum leptin concentrations or measures of adiposity. [ We limited our search to studies of women published in English after 1994, when leptin was discovered. We also searched the reference lists of articles found in this way. We included studies only if they enrolled healthy postmenopausal (surgical or natural) women who were receiving HT. In addition to varied therapeutic regimens of HT, we included tibolone (a synthetic steroid that selectively regulates estrogenic activity) and raloxifene (a nonsteroidal benzothiophene that selectively modulates ERs). 19 Studies were further evaluated to determine if leptin and adiposity were monitored at baseline and throughout a treatment period of at least 2 months. Although the review focuses on the effects of exogenous estrogen on leptin, data on leptin are impossible to interpret without taking fat mass changes into account because leptin is so closely linked to total adipose tissue mass. 21 Exclusion criteria included studies that did not report serum leptin concentrations, studies without HT intervention, studies with multiple interventions, and studies that monitored serum leptin concentrations for less than 1 month. Out of an initial sample of 40 studies, we identified 20 that met our inclusion criteria.
METHODS

From
Of the 20 studies included in this review, six studies observed serum leptin levels during a 6-month period, and six studies observed serum leptin levels during a 12-month period. Other studies consisted of 1, 2, 3, and 4 months of observation and intervention. Out of the 20 studies included, one outlierV which observed responses to HT for 60 monthsVexists.
For this review, we classified randomized, placebo-controlled studies as the highest level of evidence. We regarded nonY placebo-controlled studies as a lower level of evidence. We did not consider evidence from other types of studies.
RESULTS
Summary of studies classified by level of evidence
We reviewed a total of 20 studies (Table 1) . Only four studies 19,22<24 were both randomized and placebo-controlled, so we consider them first.
Elbers et al 19 studied the effects of 17A-estradiol 2 mg, compared with placebo, on 12 postmenopausal women. Women in the placebo group experienced more weight gain than women in the treatment group, but body fat content did not differ significantly between groups. Nevertheless, the treatment group experienced an increase in serum leptin concentrations from 17.6 to 24.1 Kg/L after 2 months (P = 0.008). This increase differed significantly from the results for the placebo group, which showed no change in leptin from baseline to 2-month follow-up. Similarly, Yüksel et al 24 randomly assigned postmenopausal women to receive estradiol/norethisterone acetate or placebo. After 6 months of therapy, leptin levels increased in both groups, but with significantly more increase in the placebo group (P = 0.033) than in the treatment group, contradicting the findings of Elbers et al. 19 Body mass index (BMI) was not affected in either group. In contrast to both studies, Mattiasson et al 22 found no significant effect of estradiol valerate on serum leptin levels in postmenopausal women compared with a placebo group. Notably, leptin levels remained relatively stable in the treatment group while showing a trend toward higher levels after 12 months in the placebo group. This study also found no effect of ET on BMI. Finally, Cagnacci et al 23 evaluated transdermal estradiol administration versus placebo in 40 women, finding no significant effect on serum leptin or BMI.
Ten additional studies were randomized 24<31 or semirandomized 25, 26 (ie, some participants were randomly assigned to groups, whereas others were allowed to choose their groups) but used no placebos. Castelo-Branco et al 27 studied 333 healthy postmenopausal women for 1 year. Women were randomly allocated to one of three different doses of norethisterone, continuously combined with a fixed dose of 17A-estradiol for intranasal or oral administration. Both intranasal and oral therapies raised leptin levels after 24 weeks (P G 0.001). BMI in this study was reported only at baseline. Tommaselli et al 28 studied 68 postmenopausal women, finding that serum leptin levels and total fat mass increased in 21 untreated women (P G 0.05), whereas women treated with tibolone (n = 23) or raloxifene (n = 24) experienced no change in serum leptin or total fat mass. In a related study by Di Carlo et al, 29 serum leptin levels increased in 22 control women who did not receive transdermal 17A-estradiol and nomegestrol (P G 0.05). Women who received treatment showed a trend toward reduced leptin levels while maintaining total fat mass and percent fat mass, a finding that could indicate improved leptin sensitivity. In a prospective comparative study by Dedeo?lu et al, 30 97 postmenopausal women were randomly assigned to no treatment, HT, or tibolone. Untreated women had lower leptin levels (P G 0.005), whereas after 6 months of treatment, the HT group had higher leptin levels (P G 0.05) and the tibolone group had lower leptin levels (P G 0.001). In the same study, women who received either HT or no treatment experienced no change in total fat mass, but the tibolone group saw a reduction in fat mass (P G 0.05), potentially accounting for the reduction in serum leptin levels.
A study by Kristensen et al 25 had the longest follow-up period among studies in our review, collecting data 5 years 
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after participants were semirandomized to receive either HT or no treatment. Leptin levels were higher in both treatment and control groups at 5-year follow-up, although increases were more pronounced in controls. Similarly, fat mass increased in both groups, but the increase was 2.4 times higher in controls than in the treatment group (P G 0.05). Adjusted analyses demonstrated no effect of HT on leptin, independent of differences in fat mass. In a less extensive study, Laivuori et al 31 randomized a small group of postmenopausal women to receive either oral or transdermal HT. After 1 year of treatment, they found no effect on serum leptin levels. Konukoglu et al 32 grouped study participants into premenopausal and postmenopausal women and found that premenopausal women had higher serum leptin levels (P G 0.001) than postmenopausal women. They also found that leptin levels were elevated after 6 months of HT in 45 women (P G 0.001). However, studies by Petzel et al, 33 Nar et al, 34 and Lambrinoudaki et al 26 found no significant effect of HT on serum leptin levels. Finally, six studies 35<40 were classified at our lowest level of evidence, as they neither randomized participants nor used a placebo. Lavoie et al 35 studied the effects of HT on postmenopausal women in younger (45-55 y) and older (70-80 y) cohorts. They found that serum leptin levels increased more in younger women (P G 0.01) after transdermal estradiol therapy. Cento et al 36 compared obese (BMI 9 25 kg/m 2 ) and nonobese (BMI G 25 kg/m 2 ) postmenopausal women with obese and nonobese premenopausal women. They found no effect of HT on serum leptin levels in either group. Although they found higher baseline leptin levels in obese premenopausal women than in their postmenopausal counterparts (P G 0.05), it is uncertain whether this difference was directly related to hypoestrogenism, aging, or other potential factors. Tommaselli et al 37 studied serum leptin levels 6 months after bilateral ovariectomy in women who received estradiol, raloxifene, or no HT, finding that leptin levels increased in women without HT (P G 0.01). They also monitored BMI, which increased nonsignificantly in women without HT. Leptin levels remained unchanged in women who received estradiol or raloxifene. Studies by Gol et al 38 and Panidis et al 40 found no effect of HT on serum leptin levels. Figure 1 categorizes all studies in our review according to their findings on the effects of HT on endogenous serum leptin levels, with studies organized in subgroups according to study design. Among all studies and subgroups, the majority showed no effect of HT.
Results of subgroup analyses by weight status
Among the studies that used randomization but no placebo, four studies 25, 26, 30, 32 also performed subgroup analyses to examine whether exogenous estrogen's effect on serum leptin levels varied according to weight status. Dedeo?lu et al 30 found that leptin levels in all participants at baseline and 6-month follow-up were significantly higher in overweight women, regardless of HT or tibolone treatment. The same study also found that leptin levels in overweight women who were treated with tibolone did not decrease as much as leptin levels in lean women who received the same treatment (35% vs 48.1%). Similarly, lean women who received HT experienced larger increases in leptin levels than did overweight women who received the same treatment (20% vs 4.9%). Kristensen et al 25 divided participants into nonobese (BMI G 25 kg/m 2 ) and obese (defined as BMI 9 25 kg/m 2 ) groups. When subgroups of HT-using obese women were analyzed separately, there was a greater effect of treatment on fat mass accumulation in nonobese participants, but no obesity-related differences in the effects of HT on leptin levels were seen. Results of the latter analyses were not shown. Konukoglu et al 32 studied obese (BMI 9 27 kg/m 2 ) and nonobese (BMI G 27 kg/m 2 ) premenopausal and postmenopausal women. After 6 months of HT, obese women experienced a larger increase in serum leptin levels than did nonobese women (29.05 vs 14.78 ng/mL). However, as a whole, subgroup analyses suggested that provision of HT among overweight and obese women had little or no effect on leptin levels, independent of BMI. In sum, two of four studies FIG. 1 . Subgroupings of studies characterized by the effects of hormone therapy (HT) on serum leptin levels. Studies were categorized by level of evidence, with randomized, placebo-controlled studies being the highest level, followed by randomized, nonYplacebo-controlled studies and, finally, nonrandomized, nonYplacebo-controlled studies as the lowest level of evidence. Randomized, placebo-controlled studies were the least prominent in our review. Randomized, nonYplacebo-controlled studies and nonrandomized, nonYplacebo-controlled studies were fairly comparable in prevalence. Studies were also categorized by the increase in serum leptin levels, depending on the presence of HT. Overall, our findings show that HT has no effect on serum leptin levels.
showed less benefit of treatment on body weight or leptin levels in subgroups of overweight and obese women.
Summary of studies classified by findings
Studies that found higher serum leptin levels in women who did not receive ET 24, 25, 28, 29, 37, 39 also found that women who received ET avoided body composition changes associated with menopause. Women without ET showed a parallel increase in serum leptin levels along with body fat content (total or percentage) or BMI. Most studies in this subgroup had relatively small sample sizes and short time frames, enrolling fewer than 25 women in each study group and extending for a maximum of 6 to 12 months. The principal exception is the study by Kristensen et al, 25 which included 267 women and lasted 5 years, making it the longest study in this review. However, that study was only partially randomized and did not use a placebo.
Five studies 19, 27, 30, 32, 35 reported higher serum leptin levels in women who received hormonal intervention. These studies showed a consistent trend of higher leptin levels without any changes in adiposity or body weight. Castelo-Branco et al 27 studied 333 postmenopausal women for 1 year in a randomized trial without placebo. This was the largest and longest study to find higher serum leptin levels in postmenopausal women who received estrogen treatment. Although it monitored the same dose of estrogen with different doses of norethisterone, findings demonstrated that intranasal and oral ETs produce the same result.
Most studies in our review found no effect of estrogen administration on serum leptin levels. Studies that yielded this finding generally used randomization but did not include a placebo and had limited sample sizes. Most studies with this finding were also of short duration, with three studies lasting for 1 year and the rest lasting for 6 months or less. A partial exception is the study by Mattiasson et al, 22 who used a randomized, placebo-controlled design to examine postmenopausal women for 1 year. Although serum leptin levels remained unchanged, percent fat mass decreased in the group that received estradiol. Their result represents a deviation from body composition changes typically associated with menopause.
Summary of studies classified by duration of HT
Of the six studies that lasted at least 12 months, four studies 27<29,39 showed an increase in serum leptin levels in the groups that received placebo or no HT. Two studies 31, 40 showed no difference in leptin levels.
DISCUSSION
This review encompasses studies that evaluated the effects of ET on endogenous serum leptin levels, weight gain, and adiposity in postmenopausal women. These studies yielded mixed results, with findings running the gamut from higher levels to lower levels to no change at all. Such variability may be the result of differences in study samples and designs (eg, time since menopause, ET dose and type, length of study). In addition, the quality of evidence in these studies is relatively low. Most studies included some sort of randomization of study participants but no placebo. Only 4 of 20 studies 19,22<24 were randomized controlled trials with a placebo. This more rigorous subset showed no consistent effect of ET on leptin levels. Overall, most trials reviewed showed no effect of ET on leptin levels.
Our current understanding of leptin's function and its relationship with estrogen and adiposity suggests that withdrawal of estrogen by ovariectomy or menopause should lead to higher leptin levels and more accumulation of body fat. Consistent with this, recent studies have shown that mice lacking ER-> have higher fat mass, and that mice and humans lacking aromatase develop obesity and hyperlipidemia. 41 A related study by Kakolewski et al 42 found that ovariectomy in female rats lowered serum estrogen to a negligible level and resulted in a 22% increase in body weight after 10 weeks. In rats, such weight gain can be reversed by estrogen administration, suggesting a causal role for estrogen depletion in this form of obesity. 41 Theoretically, the replacement of endogenous estrogen concentrations with exogenous estrogen supplements should therefore reverse these changes.
Six studies 24, 25, 28, 29, 37, 39 of postmenopausal women in fact demonstrated increases in serum leptin levels in women without hormonal intervention, but not in women with HT. For untreated women, this subgroup of studies reported a significant increase in BMI or body fat content (total or percentage) along with increases in serum leptin levels, consistent with the current understanding how leptin levels rise with adiposity. HT prevented these changes in women who received it. Of note, the subgroup of six articles included only one randomized, placebo-controlled study, 24 along with one randomized, nonYplacebo-controlled study 25 extending for 5 years. Although these selected findings support the hypothesis that HT prevents menopause-associated changes in weight and body composition, these observations are not uniform across studies, and HT has no consistent effect on suppression of weight gain or improvement of leptin sensitivity.
In contrast, several studies reported an increase in leptin levels among treated women, 19, 27, 30, 32, 35 independent of change in fat mass or BMI. One potential explanation for these observations is the development of leptin resistance, which is attributed to impaired cellular leptin receptor signaling in key hypothalamic brain areas associated with feeding and metabolism, 43 impaired ability of leptin to cross the blood-brain barrier, or both. 44 Studies that found elevated serum leptin but no change in fat mass or BMI typically had small sample sizes. However, one such study in our review included the largest number of participants. 27 Thus, a proportion of the results indicate that hormonal intervention increases serum leptin levels without affecting adiposity. These findings might be indicative of changes in leptin's central action, such that rising leptin levels are required to maintain stable body weight.
Limitations of this review include the fact that the studies recorded body weight and leptin levels but few studies measured adiposity or changes in either subcutaneous or visceral fat deposits, and results could have differed if these endpoints had been assessed. Moreover, the duration of most studies was less than 12 months, arguably an inadequate time frame to observe significant changes in energy balance. Of note, none of the six studies of at least 1 year duration demonstrated increases in leptin levels in HT-treated groups, although leptin levels rose in untreated women in four of the studies. Finally, some studies described findings on selective ER agents 26, 28, 33, 37, 38, 40 whose effects on serum leptin levels and body weight are poorly understood.
HT has been shown to protect against colorectal cancer 45 and bone loss. 46 Unfortunately, prolonged used of combined HT during menopause is associated with a higher risk of breast cancer 47 and thromboembolic events. 48 As a result, current recommendations for estrogen or estrogen plus progesterone to alleviate or prevent postmenopausal symptoms are for a short duration only.
CONCLUSIONS
Despite evidence from rodent studies, we find no clear evidence for any effect of hormonal intervention on serum leptin levels in human clinical studies. Clinicians should be aware that women may receive misleading information from popular media or Web sites that cite isolated findings or appeal to animal studies to promote the beneficial effects of estrogen. Overall, given the inconsistent effects of exogenous estrogen on altering leptin or attenuating postmenopausal weight gain, any potential benefits need to be considered in relation to the cardiovascular and neoplastic risks associated with prolonged HT.
